Do you want to read an article? Please log in or register.
Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur J Cancer
Matsumoto K, Yamamoto Y, Shiroyama T, Kuge T, Miyazaki A, Komuta K, Tamiya M, Nishino K, Tsukaguchi A, Tamiya A, Mihashi Y, Uchida J, Mori M, Yamauchi K, Suzuki H, Kinehara Y, Moritomo K, Shoshihara N, Machiyama H, Kanaoka K, Tobita S, Ueno K, Niki T, Tetsumoto S, Nishikawa Y, Morimura O, Kato S, Yoneda M, Azuma K, Osa A, Minami T, Nagatomo I, Takeda Y, Kumanogoh A
doi: 10.1016/j.ejca.2026.116902
Interstitial Lung DiseaseLung Cancer
Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study
Thorax
Karayama M, Miyashita K, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Inui N, Suda T
doi: 10.1136/thorax-2025-223430
Lung Cancer
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial
Nat Commun
Zeng L, Ruan Z, Yan H, Qin H, Zeng Z, Zou C, Huang Z, Jiang W, Dai J, Xu S, Song L, Chen Y, Zhang Y, Zeng F, Wei S, Chen S, Liu L, Xiong Y, Wang Z, Deng J, Zhang X, Sun Y, Yang D, Zhou C, Yang H, Li Y, Deng L, Xu Q, Fang C, Chen X, Wang J, Li T, Zhang G, Zhou H, Yang N, Zhang Y
doi: 10.1038/s41467-025-67262-x
Lung Cancer
CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)
Lung Cancer
Martin LW, Wang X, Kozono D, Urbanic J, Graziano S, Osarogiagbon R, Mehran R, Wain J, Bestvina C, Wolf S, Patel JD, Stinchcombe T
doi: 10.1016/j.lungcan.2026.109374
RECOMMENDED
Lung Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336
Lung Cancer
Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer a Systemic Review and Meta-analysis
Clin Lung Cancer
Choucair K, Jang H, Jalal SI, Hadid T, Uprety D, Kim S, Mamdani H
doi: 10.1016/j.cllc.2025.10.014
Lung Cancer
Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee
J Thorac Oncol
Zhu H, Al Saifi S, Bahig H, Cooper A, Abrão FC, Corrales L, Faivre-Finn C, Filippi AR, Fitzgerald B, Khosla D, Lam VK, Le X, Menezes V, Newsom-Davis T, Qin A, Putora PM, Munoz-Schuffenegger P, Siva S, Yu NY, Louie AV
doi: 10.1016/j.jtho.2025.11.006
Lung Cancer
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol
Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L
doi: 10.1016/S1470-2045(26)00282-2
Lung Cancer
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis
Semin Oncol
Ganatra N, Thompson J, Desai R, Doshi J, Jain P, Pasnoor DS, Jain A
doi: 10.1016/j.seminoncol.2025.152431